Skip to content

Price / sales at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
3.4×-1.2×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
3.1×-2.7×
XER
Xeris Biopharma Holdings, Inc.XERS
3.2×-0.6×
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
7.7×+0.5×
Theravance Biopharma logo
Theravance BiopharmaTBPH
7.6×+0.8×
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
166.6×+109×

Other financials

Income statement

See full
Revenue$36.2M+77.5%
Gross profit$34.3M+80.1%
Operating income$52.1M+1,073%
Net income$37.9M+1,323%
EPS (diluted)$0.60+1,100%

Balance sheet

See full
Cash & equivalents$95.6M+156%
Total debt$1.1M-98.1%
Total equity$205.8M+402%
Total assets$278.6M+61.3%

Cash flow

See full
Operating cash flow$6.1M+175%
CapEx$35.0K-64.6%
Free cash flow$6.1M+173%

Valuation

See full
Market cap$773.23M+56.4%
Enterprise value$678.78M+30.8%
P/E6.2×

Profitability

See full
Gross margin86.1%+7.2pp
Operating margin-103.9%-43.0pp
Net margin101.6%+60.1pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity100.7%+60.3pp
Debt / equity-1.5×
Current ratio4.9×+1.9×

Where this comes from

Calculated from Zevra Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s price / sales?
Zevra Therapeutics, Inc. (ZVRA) reported price / sales of 4.5× in Q1 2026.
How has Zevra Therapeutics, Inc.'s price / sales changed year-over-year?
Zevra Therapeutics, Inc.'s price / sales decreased by 55.2% year-over-year, from 10× to 4.5×.
What is the long-term trend for Zevra Therapeutics, Inc.'s price / sales?
Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s price / sales has grown at a 4.9% compound annual growth rate (CAGR), from 3.7× to 4.7×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.